ICH E 14 Q & A ( R 1) document: perspectives on the updated recommendations on thorough QT studies

The I nternational C onference on H armonization ( ICH ) guidance ICH E 14 provides recommendations, focusing on a clinical ‘thorough QT / QT c ( TQT ) study’, to evaluate the QT liability of a drug during its development. An I mplementation W orking G roup ( IWG ) was also established to assist the sponsors with any uncertainties and clarify any ambiguities. In A pril 2012, the IWG updated its J une 2008 version of the Q uestions and A nswers document to address additional issues. These include the gender of the study population, a reasonable approach to evaluating QT c changes in late stage clinical development and the recommended approach to correcting the measured QT interval. This commentary provides our observations and, when appropriate, recommendations, on these issues. We review briefly evidence that suggests that (i) the greater QT effect observed in females is not entirely related to differences in drug exposure and (ii) the Fridericia correction of measured QT interval is adequate for a majority of TQT studies. Until further evidence suggests otherwise, we recommend balanced gender representation in TQT studies, unless warranted otherwise, and for positive studies, subgroup analysis of key data by common demographic variables including the gender and ethnicity. We provide a general scheme for ECG monitoring in late phase clinical trials and consider that while intensive monitoring and centralized reading of ECGs in late phase clinical trials is the norm when a TQT study is positive, there are other circumstances that also call for high quality ECG reading. Therefore, locally read ECGs should only be acceptable as long as accurate high quality ECG data can be guaranteed.